Brief: Eyepoint Says Previously Reported Positive Phase 2 Davio 2 Topline Results Showing All Primary & Secondary Endpoints Were Met

EyePoint

03/02/2024 21:22

Feb 3 (Reuters) - EyePoint Pharmaceuticals Inc  EYPT.O :
    * EYEPOINT PHARMACEUTICALS ANNOUNCES TWO PRESENTATIONS OF
TOPLINE
DATA WITH ADDITIONAL SUBGROUP ANALYSES FROM THE PHASE 2 DAVIO 2
CLINICAL TRIAL OF EYP-1901 FOR THE TREATMENT OF WET AGE-RELATED
MACULAR DEGENERATION
    * EYEPOINT: HIGHLIGHT PREVIOUSLY REPORTED POSITIVE PHASE 2
DAVIO 2
TOPLINE RESULTS SHOWING ALL PRIMARY AND SECONDARY ENDPOINTS WERE
MET

Source text for Eikon:  ID:nGNX32VGBC 
Further company coverage:  EYPT.O 

 ((Reuters.Briefs@thomsonreuters.com;))